Aplastic anemia
Drug research and approvals for aplastic anemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 69 studies of aplastic anemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 3 approved and 7 open orphan designations naming it.
- Recruiting worldwide: 69
- Trials authorized in Canada: 0
- FDA orphan approvals: 3
- EU medicines: 0
- Aplastic Anemia Life-Course Cohort StudyNCT07930793 · Not reported · Institute of Hematology & Blood Diseases Hospital, China · starts Jan 1, 2012
- Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi AnemiaNCT07901959 · Phase 1 · Rockefeller University · starts Oct 14, 2026
- Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National…NCT07877727 · Not reported · Istituto Giannina Gaslini · starts May 29, 2025
- Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaNCT07714512 · Phase 1 / Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Jun 30, 2026
- A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure SyndromesNCT07712562 · Phase 1 / Phase 2 · Dren Bio · starts Aug 14, 2026
- MRI as Noninvasive Innovative Approach in Detection and Monitoring of Malignant Oral Lesions in Fanconi Anemia PatientsNCT07649031 · Not reported · University of Minnesota · starts Jun 23, 2026
- Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic…NCT07629947 · Not applicable · Peking University People's Hospital · starts Jun 15, 2026
- A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAANCT07586735 · Not reported · Peking University People's Hospital · starts Jun 1, 2026
- Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRSNCT07578675 · Not reported · Institute of Hematology & Blood Diseases Hospital, China · starts Oct 11, 2025
Approved 4
- EltrombopagThrombopoietin receptor agonist
- PrednisoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
Phase 3 7
- CyclosporineCyclophilin A modulator
- CyclophosphamideDNA inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- MethotrexateDihydrofolate reductase inhibitor
- Fludarabine
- Hetrombopag olamineThrombopoietin receptor agonist
- Nandrolone
Phase 2 12 of 16
- AlemtuzumabCAMPATH-1 antigen inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- RomiplostimThrombopoietin receptor agonist
- AvatrombopagThrombopoietin receptor agonist
- RituximabB-lymphocyte antigen CD20 binding agent
- Antilymphocyte immunoglobulin (horse)
- LevamisoleNicotinic acetylcholine receptor alpha subunit agonist
- DaclizumabInterleukin-2 receptor inhibitor
- 2-mercaptoethanesulfonic acid
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
Phase 1 or earlier 5
- DanazolProgesterone receptor agonist
- PentostatinAdenosine deaminase inhibitor
- AlefaceptT-cell surface antigen CD2 inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
- Ancestim
How its trials ended
302 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 58 whose ending is known, 38% met their primary endpoint, 9% missed it and 53% stopped early.
- Completed, result not reported10133%
- Ongoing9030%
- Status unknown5318%
- Met its primary endpoint227%
- Stopped: enrollment or feasibility134%
- Stopped: other or unclear124%
- Missed its primary endpoint52%
- Stopped: sponsor or business decision31%
- Stopped: lack of efficacy21%
- Stopped: safety1<1%
| Dec 5, 2025 | OmisirgeTreatment of adults and pediatric patients 6 years of age and older with severe aplastic anemia (SAA) following reduced intensity… | Gamida Cell Ltd. | Approved |
| Nov 16, 2018 | PromactaPROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2… | Novartis Pharmaceuticals Corp. | Approved |
| Aug 26, 2014 | PromactaTreatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. | Novartis Pharmaceuticals Corp. | Approved |
| Apr 4, 2025 | Cord blood derived T regulatory cellsTreatment of aplastic anemia | Cellenkos Inc | Designated |
| Nov 27, 2019 | RomiplostimTreatment of aplastic anemia | Amgen Inc. | Designated |
| May 27, 2015 | Adult hemogenic endothelial cellsTreatment of aplastic anemia | HemoGenyx LLC | Designated |
| Feb 18, 2013 | Allogeneic ex-vivo expanded placental adherent stromal cellsTreatment of Aplastic Anemia | Pluri Biotech Ltd. | Designated |
| Nov 3, 1995 | EtiocholanedioneTreatment of aplastic anemia. | SuperGen, Inc. | Designated |
| Jun 17, 1991 | Interleukin-1 alpha, human recombinantFor hematopoietic potentiation in aplastic anemia. | Immunex Corporation | Designated |
| Sep 25, 1989 | MolgramostimTreatment of aplastic anemia. | Schering Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA